Diese Website verwendet Cookies, damit wir dir die bestmögliche Benutzererfahrung bieten können. Cookie-Informationen werden in deinem Browser gespeichert und führen Funktionen aus, wie das Wiedererkennen von dir, wenn du auf unsere Website zurückkehrst, und hilft unserem Team zu verstehen, welche Abschnitte der Website für dich am interessantesten und nützlichsten sind.
Ibex’s gastric solution demonstrated outstanding outcomes in detecting gastric cancer in a multi-site study, supporting quality diagnosis, enhanced lab efficiency and quality control
Tel Aviv, Israel, June 15, 2022 – Ibex Medical Analytics, the pioneer in AI-powered cancer diagnostics, today announced CE-Mark for its gastric solution that supports pathologists in the detection of various types of gastric cancer. With this first-of-its-kind solution becoming generally available, Ibex offers the richest portfolio of artificial intelligence (AI) solutions in pathology, enabling detection of cancer and other pathologies in gastric, breast and prostate biopsies.
Gastric cancer is among the most common malignant diseases in both men and women worldwide, with over a million new cases every year and a relatively poor prognosis. Pathologists play a crucial role in the detection and diagnosis of gastric cancer, with their assessments being vital for reaching correct treatment decisions by oncologists and improving patient survival rates.
Over the last several years there has been an increase in overall cancer incidence, and rapid advances in personalized medicine have resulted in increases in the complexity of cancer diagnosis. Coupled with a global decline in the number of pathologists, these trends have led to growing workloads imposed on pathology departments. Clearly, there is a growing need for automated solutions and decision-support tools that help pathologists detect cancer to the utmost accuracy more rapidly, while enabling comprehensive and affordable quality control.
Ibex’s AI platform is the most widely deployed AI technology in pathology, and Ibex now partners with laboratories, hospitals and health systems to implement AI for the diagnosis of gastric biopsies. The gastric solution is an integrated diagnostics solution that supports pathologists in the detection of gastric cancer, H. pylori and other important clinical findings and in enabling shorter turnaround times and optimized diagnostic workflows1. The solution was developed by a team of pathologists, data scientists and software engineers who implemented advanced Deep Learning technologies and trained algorithms on more than a million image samples, scanned from biopsy slides digitized using digital pathology.
The CE Mark follows pioneering results from a blinded, multi-site clinical study at Medipath, the largest pathology network in France and at Maccabi Healthcare Services, the second largest health network in Israel. The gastric solution demonstrated very high accuracy in detecting various types of gastric cancer, as well as Helicobacter pylori (H. pylori – a common gastric bacterial infection and a precursor for cancer), neuroendocrine lesions, dysplasia, adenoma and additional pathologies. These results validate the robustness of the solution and support its adoption by pathology institutes that aim to improve their diagnostic quality and enhance productivity.
“Diagnosis of gastric biopsies remains a challenging task for pathologists. Gastric cancers are relatively scarce, often minute and sometimes easy to miss”, said Judith Sandbank, MD, Director of the Pathology Institute at Maccabi Healthcare Services2, and the principal investigator in the study. “We were impressed with the successful outcomes and the very high accuracy demonstrated by Ibex in detection of different cancer types. It’s also encouraging to see an AI solution that goes beyond cancer detection to accurately identify H. pylori, and provide additional insights on dysplasia, lymphoma, gastritis and other pathologies. We have already started to use the gastric solution in Maccabi and it helped us improve the quality of cancer diagnosis and patient care. I am looking forward to seeing this technology now becoming widely available at pathology departments around the world.”
“We are proud to obtain this first-of-its-kind CE-Mark for AI-powered GI diagnostics in pathology, following excellent performance in a multi-site clinical study” said Chaim Linhart, PhD, Co-founder and CTO of Ibex at Ibex Medical Analytics. “We trained the Deep Learning models for gastric on more than a million image samples from multiple labs to ensure it can accurately detect not only cancer but also a multitude of other clinically relevant features that impact future treatment for patients. Ibex now offers an unprecedented breadth of clinical applications, and this approval will enable our growing customer base to expand the usage of AI technology and provide their pathologists with new insights as they review gastric biopsies, improving the quality of cancer diagnosis and care.”
The study outcomes will be presented at the European Congress on Digital Pathology which takes place in Berlin between June 15-18 (Ibex presents at booth B11).
 Sandbank et al. Validation and Clinical Deployment of an AI-Based Solution for Detection of Gastric Adenocarcinoma and Helicobacter pylori in Gastric Biopsies. USCAP 2022.
 Dr. Sandbank also serves as the Chief Medical Officer at Ibex Medical Analytics